1h Free Analyst Time
The publisher has been monitoring the microbial products market and it is poised to grow by $18.41 bn during 2022-2026, progressing at a CAGR of 12.20% during the forecast period. The report on the microbial products market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high demand for microbial products in the pharmaceutical industry and advances in discovery, therapeutics, and diagnostics of microbes.
The microbial products market analysis includes the application segment and geographic landscape.
The microbial products market is segmented as below:
By Application
- Pharmaceutical
- Diagnostics
- Biotechnology
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the changes in the lifestyles of human beings and the environment as one of the prime reasons driving the microbial products market growth during the next few years.
The report on microbial products market covers the following areas:
- Microbial products market sizing
- Microbial products market forecast
- Microbial products market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading microbial products market vendors that include bioMerieux SA, GlaxoSmithKline Plc, Kyowa Hakko Bio Co. Ltd., Merck KGaA, NovaMedica, Novartis AG, Pfizer Inc., Sanofi SA, Thermo Fisher Scientific Inc., and Valent BioSciences LLC. Also, the microbial products market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2021
- Market outlook: Forecast for 2021 - 2026
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Application
- Market segments
- Comparison by Application
- Pharmaceutical - Market size and forecast 2021-2026
- Diagnostics - Market size and forecast 2021-2026
- Biotechnology - Market size and forecast 2021-2026
- Market opportunity by Application
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2021-2026
- Europe - Market size and forecast 2021-2026
- Asia - Market size and forecast 2021-2026
- ROW - Market size and forecast 2021-2026
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- bioMerieux SA
- GlaxoSmithKline Plc
- Kyowa Hakko Bio Co. Ltd.
- Merck KGaA
- NovaMedica
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Thermo Fisher Scientific Inc.
- Valent BioSciences LLC
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2021 - 2026 ($ million)
- Global market: Year-over-year growth 2021 - 2026 (%)
- Five forces analysis 2021 & 2026
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2021
- Application - Market share 2021-2026 (%)
- Comparison by Application
- Pharmaceutical - Market size and forecast 2021-2026 ($ million)
- Pharmaceutical - Year-over-year growth 2021-2026 (%)
- Diagnostics - Market size and forecast 2021-2026 ($ million)
- Diagnostics - Year-over-year growth 2021-2026 (%)
- Biotechnology - Market size and forecast 2021-2026 ($ million)
- Biotechnology - Year-over-year growth 2021-2026 (%)
- Market opportunity by Application
- Customer landscape
- Market share By Geographical Landscape 2021-2026 (%)
- Geographic comparison
- North America - Market size and forecast 2021-2026 ($ million)
- North America - Year-over-year growth 2021-2026 (%)
- Europe - Market size and forecast 2021-2026 ($ million)
- Europe - Year-over-year growth 2021-2026 (%)
- Asia - Market size and forecast 2021-2026 ($ million)
- Asia - Year-over-year growth 2021-2026 (%)
- ROW - Market size and forecast 2021-2026 ($ million)
- ROW - Year-over-year growth 2021-2026 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- bioMerieux SA - Overview
- bioMerieux SA - Business segments
- bioMerieux SA - Key offerings
- bioMerieux SA - Key customers
- bioMerieux SA - Segment focus
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Key customers
- GlaxoSmithKline Plc - Segment focus
- Kyowa Hakko Bio Co. Ltd. - Overview
- Kyowa Hakko Bio Co. Ltd. - Product and service
- Kyowa Hakko Bio Co. Ltd. - Key offerings
- Kyowa Hakko Bio Co. Ltd. - Key customers
- Kyowa Hakko Bio Co. Ltd. - Segment focus
- Merck KGaA - Overview
- Merck KGaA - Product and service
- Merck KGaA - Key offerings
- Merck KGaA - Key customers
- Merck KGaA - Segment focus
- NovaMedica - Overview
- NovaMedica - Product and service
- NovaMedica - Key offerings
- NovaMedica - Key customers
- NovaMedica - Segment focus
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key offerings
- Novartis AG - Key customers
- Novartis AG - Segment focus
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Key customers
- Pfizer Inc. - Segment focus
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key offerings
- Sanofi SA - Key customers
- Sanofi SA - Segment focus
- Thermo Fisher Scientific Inc. - Overview
- Thermo Fisher Scientific Inc. - Business segments
- Thermo Fisher Scientific Inc. - Key offerings
- Thermo Fisher Scientific Inc. - Key customers
- Thermo Fisher Scientific Inc. - Segment focus
- Valent BioSciences LLC - Overview
- Valent BioSciences LLC - Product and service
- Valent BioSciences LLC - Key offerings
- Valent BioSciences LLC - Key customers
- Valent BioSciences LLC - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- bioMerieux SA
- GlaxoSmithKline Plc
- Kyowa Hakko Bio Co. Ltd.
- Merck KGaA
- NovaMedica
- Novartis AG
- Pfizer Inc.
- Sanofi SA
- Thermo Fisher Scientific Inc.
- Valent BioSciences LLC
